サマリー

中東とアフリカの線維性疾患治療市場は、2023年から2030年の予測期間に6.0%の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。
市場セグメンテーションを行います：
中東・アフリカ線維性疾患治療市場：治療法別（投薬、臓器移植、酸素療法、その他）、用途別（特発性肺線維症、肝硬変、腎線維症、皮膚線維症、その他）、エンドユーザー（病院、専門クリニック、学術・研究機関、その他）、流通チャネル（病院薬局、小売薬局、その他）、国（南アフリカ、サウジアラビア、UAE、エジプト、クウェート、バーレーン、イスラエル、その他の中東・アフリカ地域)

中東・アフリカの線維性疾患治療市場の成長に寄与する主な要因としては、以下のものが挙げられます：

- 線維症治療における技術的進歩
- たばこを吸う人の増加

市場プレイヤー
中東・アフリカの線維性疾患治療市場の主要な市場プレイヤーを以下に紹介します：

- ベーリンガーインゲルハイムインターナショナルGmbH
- アッヴィー社（AbbVie Inc.
- ブリストル・マイヤーズ スクイブ・カンパニー
- バイオMX
- ギリアド・サイエンシズ社（Gilead Sciences, Inc.
- テバ・ファーマシューティカル・インダストリーズ社
- サンド・インターナショナル社

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 TREATMENT TYPE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET END USER COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 51
4.1 PORTER'S 5 FORCES 52
4.2 PESTEL ANALYSIS 53
5 EPIDEMIOLOGY 54
5.1 INCIDENCE OF ALL BY GENDER 54
5.2 TREATMENT RATE 54
5.3 MORTALITY RATE 54
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55
5.5 PATIENT TREATMENT SUCCESS RATE 55
6 INDUSTRY INSIGHTS 56
6.1 PATENT ANALYSIS 56
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56
6.4 KEY PRICING STRATEGIES 57
6.5 KEY PATIENT ENROLLMENT STRATEGIES 58
7 MERGERS AND ACQUISITIONS 60
7.1 LICENSING: 60
7.2 COMMERCIALIZATION AGREEMENTS 60
8 PIPELINE ANALYSIS 61
8.1 PHASE 1 61
8.2 PHASE 2 61
8.3 PHASE 3 61
9 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62
9.1 FDA APPROVALS 62
9.2 EMA APPROVALS 63
10 MARKET OVERVIEW 64
10.1 DRIVERS 66
10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66
10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66
10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67
10.2 RESTRAINTS 67
10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67
10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67
10.3 OPPORTUNITIES 68
10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68
10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68
10.4 CHALLENGES 69
10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69
10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69
11 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70
11.1 OVERVIEW 71
11.2 MEDICATION 73
11.2.1 INTEDANIB (OFEV) 74
11.2.2 PIRFENIDONE (ESBRIET) 74
11.3 ORGAN TRANSPLANTATION 74
11.4 OXYGEN THERAPY 75
11.5 OTHERS 76
12 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77
12.1 OVERVIEW 78
12.2 IDIOPATHIC PULMONARY FIBROSIS 81
12.3 HEPATIC CIRRHOSIS 81
12.4 RENAL FIBROSIS 82
12.5 CUTANEOUS FIBROSIS 83
12.6 OTHERS 84
13 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85
13.1 OVERVIEW 86
13.2 HOSPITALS 89
13.3 SPECIALTY CLINICS 90
13.4 ACADEMIC AND RESEARCH INSTITUTES 90
13.5 OTHERS 91
14 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92
14.1 OVERVIEW 93
14.2 HOSPITAL PHARMACY 96
14.3 RETAIL PHARMACY 96
14.4 OTHERS 97
15 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98
15.1 MIDDLE EAST AND AFRICA 99
15.1.1 SOUTH AFRICA 105
15.1.2 SAUDI ARABIA 107
15.1.3 U.A.E 109
15.1.4 EGYPT 111
15.1.5 KUWAIT 113
15.1.6 ISRAEL 115
15.1.7 BAHRAIN 117
15.1.8 REST OF MIDDLE EAST AND AFRICA 119
16 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 120
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 120
17 SWOT ANALYSIS 121
18 COMPANY PROFILE 122
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 122
18.1.1 COMPANY SNAPSHOT 122
18.1.2 REVENUE ANALYSIS 122
18.1.3 COMPANY SHARE ANALYSIS 123
18.1.4 PRODUCT PORTFOLIO 123
18.1.5 RECENT DEVELOPMENTS 123
18.2 GENENTECH, INC. 124
18.2.1 COMPANY SNAPSHOT 124
18.2.2 COMPANY SHARE ANALYSIS 124
18.2.3 PRODUCT PORTFOLIO 125
18.2.4 RECENT DEVELOPMENTS 125
18.3 SANDOZ INTERNATIONAL GMBH 126
18.3.1 COMPANY SNAPSHOT 126
18.3.2 COMPANY SHARE ANALYSIS 126
18.3.3 PRODUCT PORTFOLIO 127
18.3.4 RECENT DEVELOPMENTS 127
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 128
18.4.1 COMPANY SNAPSHOT 128
18.4.2 REVENUE ANALYSIS 128
18.4.3 COMPANY SHARE ANALYSIS 129
18.4.4 PRODUCT PORTFOLIO 129
18.4.5 RECENT DEVELOPMENTS 129
18.5 ACCORD HEALTHCARE U.S. 130
18.5.1 COMPANY SNAPSHOT 130
18.5.2 COMPANY SHARE ANALYSIS 130
18.5.3 PRODUCT PORTFOLIO 131
18.5.4 RECENT DEVELOPMENTS 131
18.6 ABBVIE INC. 132
18.6.1 COMPANY SNAPSHOT 132
18.6.2 REVENUE ANALYSIS 132
18.6.3 PRODUCT PORTFOLIO 133
18.6.4 RECENT DEVELOPMENTS 133
18.7 ALPINE IMMUNE SCIENCES 134
18.7.1 COMPANY SNAPSHOT 134
18.7.2 REVENUE ANALYSIS 134
18.7.3 PRODUCT PORTFOLIO 135
18.7.4 RECENT DEVELOPMENTS 135
18.8 BELLBROOK LABS 136
18.8.1 COMPANY SNAPSHOT 136
18.8.2 PRODUCT PORTFOLIO 136
18.8.3 RECENT DEVELOPMENTS 136
18.9 BIOMX 137
18.9.1 COMPANY SNAPSHOT 137
18.9.2 REVENUE ANALYSIS 137
18.9.3 PRODUCT PORTFOLIO 138
18.9.4 RECENT DEVELOPMENTS 138
18.10 BRISTOL-MYERS SQUIBB COMPANY 139
18.10.1 COMPANY SNAPSHOT 139
18.10.2 REVENUE ANALYSIS 139
18.10.3 PRODUCT PORTFOLIO 140
18.10.4 RECENT DEVELOPMENTS 140
18.11 CAMBER PHARMACEUTICALS, INC. 141
18.11.1 COMPANY SNAPSHOT 141
18.11.2 PRODUCT PORTFOLIO 141
18.11.3 RECENT DEVELOPMENTS 141
18.12 ENVEDA 142
18.12.1 COMPANY SNAPSHOT 142
18.12.2 PRODUCT PORTFOLIO 142
18.12.3 RECENT DEVELOPMENTS 142
18.13 GILEAD SCIENCES, INC. 143
18.13.1 COMPANY SNAPSHOT 143
18.13.2 REVENUE ANALYSIS 143
18.13.3 PRODUCT PORTFOLIO 144
18.13.4 RECENT DEVELOPMENTS 144
18.14 INTERCEPT PHARMACEUTICALS, INC. 145
18.14.1 COMPANY SNAPSHOT 145
18.14.2 REVENUE ANALYSIS 145
18.14.3 PRODUCT PORTFOLIO 146
18.14.4 RECENT DEVELOPMENTS 146
18.15 KITHER BIOTECH S.R.L. 147
18.15.1 COMPANY SNAPSHOT 147
18.15.2 PRODUCT PORTFOLIO 147
18.15.3 RECENT DEVELOPMENTS 147
18.16 PHARMAXIS LTD 148
18.16.1 COMPANY SNAPSHOT 148
18.16.2 REVENUE ANALYSIS 148
18.16.3 PRODUCT PORTFOLIO 149
18.16.4 RECENT DEVELOPMENTS 149
18.17 REDX PHARMA PLC. 150
18.17.1 COMPANY SNAPSHOT 150
18.17.2 REVENUE ANALYSIS 150
18.17.3 PRODUCT PORTFOLIO 151
18.17.4 RECENT DEVELOPMENTS 151
18.18 VERONA PHARMA PLC 152
18.18.1 COMPANY SNAPSHOT 152
18.18.2 REVENUE ANALYSIS 152
18.18.3 PRODUCT PORTFOLIO 153
18.18.4 RECENT DEVELOPMENTS 153
19 QUESTIONNAIRE 154
20 RELATED REPORTS 157

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, PIPELINE ANALYSIS 44
TABLE 2 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 56
TABLE 3 MIDDLE EAST & AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 57
TABLE 4 MIDDLE EAST & AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 57
TABLE 5 MIDDLE EAST & AFRICA ORGAN TRANSPLANTATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 58
TABLE 6 MIDDLE EAST & AFRICA OXYGEN THERAPY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 59
TABLE 7 MIDDLE EAST & AFRICA OTHER IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 59
TABLE 8 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 63
TABLE 9 MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 64
TABLE 10 MIDDLE EAST & AFRICA HEPATIC CIRRHOSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 65
TABLE 11 MIDDLE EAST & AFRICA RENAL FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 12 MIDDLE EAST & AFRICA CUTANEOUS FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 13 MIDDLE EAST & AFRICA OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 14 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 71
TABLE 15 MIDDLE EAST & AFRICA HOSPITALS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 72
TABLE 16 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
TABLE 17 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 18 MIDDLE EAST & AFRICA OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 19 MIDDLE EAST & AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 78
TABLE 20 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
TABLE 21 MIDDLE EAST & AFRICA RETAIL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 22 MIDDLE EAST & AFRICA OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 23 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 86
TABLE 24 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 86
TABLE 25 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 86
TABLE 26 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 86
TABLE 27 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 87
TABLE 28 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 87
TABLE 29 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 87
TABLE 30 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 87
TABLE 31 SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 88
TABLE 32 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 88
TABLE 33 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 88
TABLE 34 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 88
TABLE 35 SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 89
TABLE 36 SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 89
TABLE 37 SOUTH AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 89
TABLE 38 SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 90
TABLE 39 SAUDI ARABIA PRODUCTS, 2021-2030 (USD THOUSAND) 90
TABLE 40 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 90
TABLE 41 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 90
TABLE 42 SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 91
TABLE 43 SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 91
TABLE 44 SAUDI ARABIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 91
TABLE 45 U.A.E FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 92
TABLE 46 U.A.E MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 92
TABLE 47 U.A.E MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 92
TABLE 48 U.A.E MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 92
TABLE 49 U.A.E FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 93
TABLE 50 U.A.E FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 93
TABLE 51 U.A.E FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 93
TABLE 52 EGYPT FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 94
TABLE 53 EGYPT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 94
TABLE 54 EGYPT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 94
TABLE 55 EGYPT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 94
TABLE 56 EGYPT FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 95
TABLE 57 EGYPT FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 95
TABLE 58 EGYPT FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 95
TABLE 59 KUWAIT FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 96
TABLE 60 KUWAIT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 96
TABLE 61 KUWAIT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 96
TABLE 62 KUWAIT MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 96
TABLE 63 KUWAIT FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 97
TABLE 64 KUWAIT FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 97
TABLE 65 KUWAIT FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 97
TABLE 66 ISRAEL FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 98
TABLE 67 ISRAEL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 98
TABLE 68 ISRAEL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 98
TABLE 69 ISRAEL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 98
TABLE 70 ISRAEL FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 99
TABLE 71 ISRAEL FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 99
TABLE 72 ISRAEL FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 99
TABLE 73 BAHRAIN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 100
TABLE 74 BAHRAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 100
TABLE 75 BAHRAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 100
TABLE 76 BAHRAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 100
TABLE 77 BAHRAIN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 101
TABLE 78 BAHRAIN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 101
TABLE 79 BAHRAIN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 101
TABLE 80 REST OF MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 102